Physician profile
Sunil Babu
NPI 1891968301
$165,617.37
in general payments reported to CMS, 2019-2025
80 companies · $27K in 2025
The $27K reported for 2025 was more than what 91% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $21K · 2021: $25K · 2022: $21K · 2023: $21K · 2024: $14K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $46K · Honoraria: $7,596 · Food and Beverage: $6,128 · Travel and Lodging: $1,576 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $45,752.00 |
| Honoraria | $7,596.00 |
| Food and Beverage | $6,128.08 |
| Travel and Lodging | $1,575.64 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $189.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $26,872.41 | 2019-2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $20,115.26 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Daiichi Sankyo INC. | $14,698.04 | 2019-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $14,598.98 | 2019-2025 | Lumoxiti, Imfinzi, Airsupra |
| Kite Pharma, INC. | $12,804.04 | 2020-2022 | |
| Genentech, INC. | $12,010.70 | 2019 | |
| Cornerstone Specialty Network LLC | $9,468.00 | 2022-2024 | |
| Amgen INC. | $5,990.21 | 2019-2023 | Kyprolis, Lumakras |
| Janssen Scientific Affairs, LLC | $5,967.50 | 2020-2023 | Imbruvica |
| Janssen Biotech, INC. | $5,567.77 | 2019-2025 | Darzalex, Imbruvica, Erleada |
| Genzyme Corporation | $3,690.76 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $3,413.19 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $2,421.90 | 2021 | |
| F. Hoffmann-La Roche Ag | $2,398.40 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $2,291.31 | 2021-2025 | Fotivda |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $2,100.00 | 2024 | |
| Pfizer INC. | $2,083.65 | 2019-2025 | |
| Beigene USA, INC. | $1,953.36 | 2021-2024 | Tevimbra, Brukinsa |
| Karyopharm Therapeutics INC. | $1,907.05 | 2021-2025 | Xpovio |
| Glaxosmithkline, LLC. | $1,876.34 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,874.30 | 2019-2021 | |
| Stemline Therapeutics INC. | $1,703.96 | 2023 | Orserdu |
| Gilead Sciences, INC. | $1,421.93 | 2021-2025 | Trodelvy |
| Janssen Research & Development, LLC | $1,037.05 | 2019 | |
| Caris Mpi, INC. | $1,023.32 | 2025 | Mi Cancer Seek |
| Avyxa Pharma, LLC | $1,000.00 | 2025 | |
| Fennec Pharmaceuticals, INC. | $873.54 | 2024-2025 | Fyarro, Pedmark |
| Boehringer Ingelheim Pharmaceuticals, INC. | $520.00 | 2020 | |
| Merck Sharp & Dohme LLC | $503.66 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Beigene, LTD. | $450.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $356.07 | 2019-2023 | Alunbrig |
| Abbvie INC. | $228.36 | 2023-2025 | Venclexta |
| Regeneron Healthcare Solutions, INC. | $192.62 | 2021-2025 | Libtayo |
| Celgene Corporation | $179.56 | 2021-2023 | Pomalyst, Reblozyl |
| Incyte Corporation | $170.39 | 2021-2025 | Monjuvi, Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $169.93 | 2022-2023 | Imbruvica, Epkinly |
| Beone Medicines USA, INC. | $167.70 | 2025 | Brukinsa |
| Tempus Ai, INC | $148.05 | 2024-2025 | Xt Cdx |
| Rigel Pharmaceuticals, INC. | $143.35 | 2023-2024 | Rezlidhia, Tavalisse |
| Sobi, INC | $142.72 | 2025 | |
| Dova Pharmaceuticals | $126.42 | 2020-2021 | |
| Verastem, INC. | $122.06 | 2019 | |
| Foundation Medicine, INC. | $98.46 | 2020 | |
| Adc Therapeutics America, INC. | $91.59 | 2023 | |
| Seagen INC. | $82.36 | 2020-2022 | |
| Astellas Pharma US INC | $58.11 | 2023-2025 | Xospata, Padcev |
| Jazz Pharmaceuticals INC. | $58.07 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $57.07 | 2023-2024 | Clonoseq |
| Lilly USA, LLC | $48.75 | 2019-2022 | |
| Eisai INC. | $48.36 | 2020-2024 | |
| Genentech USA, INC. | $42.91 | 2019-2023 | Lunsumio |
| Syndax Pharmaceuticals, INC. | $26.48 | 2025 | Revuforj |
| Legend Biotech USA INC. | $25.72 | 2025 | Carvykti |
| Servier Pharmaceuticals LLC | $22.29 | 2024 | |
| Global Blood Therapeutics, INC. | $20.62 | 2022 | |
| Array Biopharma INC | $19.48 | 2019-2024 | Mektovi, Braftovi |
| Deciphera Pharmaceuticals INC. | $18.18 | 2025 | Qinlock |
| Exelixis INC. | $18.17 | 2023 | Cabometyx |
| Otsuka America Pharmaceutical, INC. | $15.82 | 2022 | |
| Immunocore Limited | $15.20 | 2025 | Kimmtrak |
| Partner Therapeutics, INC. | $14.73 | 2019 | |
| Acrotech Biopharma INC. | $13.93 | 2021 | |
| Emd Serono, INC. | $13.73 | 2019 | |
| Acceleron Pharma, INC. | $13.64 | 2021 | |
| Janssen Pharmaceuticals, INC | $9.84 | 2019 |
15 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$43,891.73 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Babu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.